English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Inflammation plays an important role in the development and progression of a variety of cardiovascular conditions, most notably coronary atherosclerosis and congestive heart failure. A number of inflammatory molecules have been implicated in these processes, including interleukin-1 (IL-1). IL-1 receptor antagonist is an endogenous inhibitor of IL- 1, which competitively binds to the IL-1 type I receptor without activating it. Anakinra is a nonglycosylated, recombinant form of human IL-1ra that, like endogenous IL-1ra, competitively inhibits IL-1 by binding the IL-1 type I receptor.

Mekanisme Kerja dan Target Molekuler Interleukin-1 receptor antagonist (Anakinra) pada Aterosklerosis